

QIAGEN NV
Form 6-K
September 24, 2012
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the month ended September 30, 2012
Commission File Number 0-28564

QIAGEN N.V.
(Translation of registrant's name into English)

Spoorstraat 50
5911 KJ Venlo
The Netherlands
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82- .

Table of Contents

QIAGEN N.V.
Form 6-K

TABLE OF CONTENTS

Item	Page
Other Information	<u>3</u>
Signatures	<u>4</u>
Exhibit Index	<u>5</u>

Table of Contents

OTHER INFORMATION

On September 21, 2012, QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) issued a press release announcing a share repurchase program that will commence on October 1, 2012. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

By:

QIAGEN N.V.

/s/ Roland Sackers

Roland Sackers

Chief Financial Officer

Date: September 24, 2012

Table of Contents

EXHIBIT INDEX

Exhibit No.	Exhibit
99.1	Press Release dated September 21, 2012

Table of Contents

Exhibit 99.1

Disclosure according to Art. 4 Para. 2 of the Regulation (EC) No. 2273/2003

The share repurchase program, announced by QIAGEN N.V. in an ad hoc announcement dated July 24, 2012, will commence on October 1, 2012.

In the time period until November 5, 2012, a first tranche of common shares of the Company having a total purchase price of up to the EUR equivalent amount of USD 10 million (without ancillary purchasing costs) shall be repurchased on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) exclusively. The first tranche is limited by the repurchase of a total number of max. 570,000 shares. The maximum purchase price per share (excluding ancillary purchase costs) will not exceed by more than 10% the EUR equivalent of the average closing price for the last five trading days prior to the day of purchase on the NASDAQ Global Select Market.

The purpose of the share repurchase is to hold the shares in treasury in order to satisfy obligations from exchangeable debt instruments and/or employee share-based remuneration plans. The Managing Board of QIAGEN N.V., upon authorization of the Supervisory Board, is thus exercising the authorization by the Annual General Meeting on June 27, 2012 to acquire own shares. The repurchase of additional tranches will be decided separately and details will be announced separately.

The repurchase program will be carried out on behalf and account of QIAGEN N.V. through a financial institution commissioned by the Company. The financial institution will decide on the timing of the share purchase independently, without being influenced by the Company.

The first tranche of the share repurchase program will be implemented in accordance with the trading terms of Art. 5 of the Regulation No. 2273/2003 of the Commission of December 22, 2003 (EC Regulation). In accordance with the EC Regulation, no purchase price may be paid that exceeds the price of the last independent trade or the highest current independent bid on the Frankfurt Stock Exchange. The higher of both values is decisive. In accordance with the EC Regulation, no more than 25% of the average daily volume of shares on the Frankfurt Stock Exchange may be acquired. The average volume of shares is based on the average daily volume traded in the twenty stock exchange trading days preceding the date of the purchase.

The share repurchase program may be suspended and resumed at any time, in line with applicable statutory regulations.

The transactions will be announced in a manner compliant with the requirements of Art. 4, Para. 4 of the EC Regulation no later than on the seventh trading day following their conclusion.

In addition, QIAGEN N.V. will provide regular updates on the progress of the share repurchase program at www.qiagen.com.

Venlo, September 21, 2012

The Managing Board

###

Contacts:

QIAGEN

Investor Relations

John Gilardi

+49 2103 29 11711

Albert F. Fleury

+1 301 944 7028

e-mail: ir@qiagen.com

Public Relations

Dr. Thomas Theuringer

+49 2103 29 11826

e-mail: pr@qiagen.com